Purposeful employs a computational workflow to identify alternative therapeutic effects of existing pharmaceuticals, enhancing drug repurposing efforts. This method addresses the lengthy development timelines and limited efficacy associated with traditional drug discovery processes.
Funding
$230K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MVFounders
Product
Problem
Traditional drug discovery for rare diseases is a lengthy and expensive process, often with limited success due to the small patient populations and complex genetic factors involved. Many rare diseases lack effective treatments, leaving a significant unmet need for patients and their families.
Solution
Purposeful leverages a computational approach to identify existing pharmaceuticals that can be repurposed for the treatment of rare diseases. By analyzing the molecular mechanisms of both drugs and diseases, Purposeful aims to find alternative therapeutic applications for already-marketed compounds, significantly reducing development timelines and costs. This AI-driven drug repurposing strategy allows for a faster and more efficient path to developing treatments for rare genetic conditions, with the goal of reversing disease phenotypes. The company focuses on identifying drugs that can address the underlying causes of these diseases, rather than just managing symptoms.
Target Audience
The primary target audience includes patients and families affected by rare diseases, as well as pharmaceutical companies and research institutions seeking to accelerate drug development for these conditions.
Features
- Computational workflow for identifying drug repurposing candidates
- Focus on rare genetic diseases with unmet medical needs
- Analysis of molecular mechanisms to match drugs with diseases
- Partnerships with research organizations and pharmaceutical companies
- Pipeline of drug candidates targeting various rare diseases, including Fragile X Syndrome and Glioblastoma